R&D Focus
- Focusing on both generic and innovative drugs with over 50 generics developed and approved in China to date (one-third of all being first generics in China); first NDA for an innovative drug (HSK3486) filed in China in June 2019 and approved in December 2020
- Over 800 scientists with extensive pharmaceutical industry experience in R&D
- Proven CMC (Chemistry, Manufacturing and Controls), Pre-Clinical and Clinical Development capabilities
- Haisco-USA has a focused product pipeline in select therapeutic areas, including anesthesia and pain management in the US and EU